You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMaleic Acid
Accession NumberDB04299  (EXPT02106)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
Prescription ProductsNot Available
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
CategoriesNot Available
CAS number110-16-7
WeightAverage: 116.0722
Monoisotopic: 116.010958616
Chemical FormulaC4H4O4
InChI KeyVZCYOOQTPOCHFL-OWOJBTEDSA-N
InChI
InChI=1S/C4H4O4/c5-3(6)1-2-4(7)8/h1-2H,(H,5,6)(H,7,8)/b2-1+
IUPAC Name
(2E)-but-2-enedioic acid
SMILES
OC(=O)\C=C\C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dicarboxylic acids and derivatives. These are organic compounds containing exactly two carboxylic acid groups.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassDicarboxylic acids and derivatives
Direct ParentDicarboxylic acids and derivatives
Alternative Parents
Substituents
  • Fatty acyl
  • Fatty acid
  • Unsaturated fatty acid
  • Dicarboxylic acid or derivatives
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Citric Acid CycleMetabolicSMP00057
Mitochondrial complex II deficiencyDiseaseSMP00548
Fumarase deficiencyDiseaseSMP00547
Mitochondrial Electron Transport ChainMetabolicSMP00355
Pyruvate dehydrogenase deficiency (E3)DiseaseSMP00550
Congenital lactic acidosisDiseaseSMP00546
Pyruvate dehydrogenase deficiency (E2)DiseaseSMP00551
2-ketoglutarate dehydrogenase complex deficiencyDiseaseSMP00549
Canavan DiseaseDiseaseSMP00175
Tyrosinemia Type 2 (or Richner-Hanhart syndrome)DiseaseSMP00369
Aspartate MetabolismMetabolicSMP00067
Argininosuccinic AciduriaDiseaseSMP00003
Carbamoyl Phosphate Synthetase DeficiencyDiseaseSMP00002
Phenylalanine and Tyrosine MetabolismMetabolicSMP00008
Urea CycleMetabolicSMP00059
Ornithine Transcarbamylase Deficiency (OTC Deficiency)DiseaseSMP00205
HypoacetylaspartiaDiseaseSMP00192
PhenylketonuriaDiseaseSMP00206
Tyrosinemia Type 3 (TYRO3)DiseaseSMP00370
ArgininemiaDiseaseSMP00357
Citrullinemia Type IDiseaseSMP00001
Warburg EffectMetabolicSMP00654
Hyperprolinemia Type IDiseaseSMP00361
Tyrosinemia Type IDiseaseSMP00218
Creatine deficiency, guanidinoacetate methyltransferase deficiencyDiseaseSMP00504
Prolidase Deficiency (PD)DiseaseSMP00207
Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency)DiseaseSMP00188
Tyrosinemia, transient, of the newbornDiseaseSMP00494
Hyperornithinemia-hyperammonemia-homocitrullinuria [HHH-syndrome]DiseaseSMP00506
Hyperprolinemia Type IIDiseaseSMP00360
HawkinsinuriaDiseaseSMP00190
Monoamine oxidase-a deficiency (MAO-A)DiseaseSMP00533
Prolinemia Type IIDiseaseSMP00208
Dopamine beta-hydroxylase deficiencyDiseaseSMP00498
Hyperornithinemia with gyrate atrophy (HOGA)DiseaseSMP00505
Arginine and Proline MetabolismMetabolicSMP00020
Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency)DiseaseSMP00362
Ornithine Aminotransferase Deficiency (OAT Deficiency)DiseaseSMP00363
Tyrosine MetabolismMetabolicSMP00006
AlkaptonuriaDiseaseSMP00169
L-arginine:glycine amidinotransferase deficiencyDiseaseSMP00507
Molybdenum Cofactor DeficiencyDiseaseSMP00203
Purine Nucleoside Phosphorylase DeficiencyDiseaseSMP00210
Mitochondrial DNA depletion syndromeDiseaseSMP00536
Purine MetabolismMetabolicSMP00050
Adenylosuccinate Lyase DeficiencyDiseaseSMP00167
Azathioprine Action PathwayDrug actionSMP00427
Adenosine Deaminase DeficiencyDiseaseSMP00144
AICA-RibosiduriaDiseaseSMP00168
Thioguanine Action PathwayDrug actionSMP00430
Disulfiram Action PathwayDrug actionSMP00429
Myoadenylate deaminase deficiencyDiseaseSMP00537
Lesch-Nyhan Syndrome (LNS)DiseaseSMP00364
Xanthine Dehydrogenase Deficiency (Xanthinuria)DiseaseSMP00220
Xanthinuria type IIDiseaseSMP00513
Adenine phosphoribosyltransferase deficiency (APRT)DiseaseSMP00535
Gout or Kelley-Seegmiller SyndromeDiseaseSMP00365
Mercaptopurine Action PathwayDrug actionSMP00428
Xanthinuria type IDiseaseSMP00512
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.874
Blood Brain Barrier+0.9017
Caco-2 permeable-0.6728
P-glycoprotein substrateNon-substrate0.8006
P-glycoprotein inhibitor INon-inhibitor0.985
P-glycoprotein inhibitor IINon-inhibitor0.9808
Renal organic cation transporterNon-inhibitor0.9583
CYP450 2C9 substrateNon-substrate0.8262
CYP450 2D6 substrateNon-substrate0.9397
CYP450 3A4 substrateNon-substrate0.8039
CYP450 1A2 substrateNon-inhibitor0.9659
CYP450 2C9 substrateNon-inhibitor0.949
CYP450 2D6 substrateNon-inhibitor0.9606
CYP450 2C19 substrateNon-inhibitor0.9773
CYP450 3A4 substrateNon-inhibitor0.9554
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9899
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.513
BiodegradationReady biodegradable0.7561
Rat acute toxicity1.6871 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9836
hERG inhibition (predictor II)Non-inhibitor0.9891
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point130.5 °CPhysProp
water solubility4.41E+005 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-0.48SANGSTER (1994)
pKa1.83LIDE,DR (1996)
Predicted Properties
PropertyValueSource
Water Solubility24.1 mg/mLALOGPS
logP0.21ALOGPS
logP-0.041ChemAxon
logS-0.68ALOGPS
pKa (Strongest Acidic)3.55ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity24.61 m3·mol-1ChemAxon
Polarizability9.35 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraGC-MSMS/MSMS1D NMR2D NMR
References
Synthesis Reference

Yasuhisha Fukumoto, Noboru Moriyama, Takashi Itoi, “Maleic acid copolymer, production thereof and scale-preventing agent containing the same.” U.S. Patent US4589995, issued August, 1933.

US4589995
General ReferenceNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

Targets

1. Aspartate aminotransferase

Kind: protein

Organism: Escherichia coli (strain K12)

Pharmacological action: unknown

Components

Name UniProt ID Details
Aspartate aminotransferase P00509 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

2. Trypanothione reductase

Kind: protein

Organism: Trypanosoma cruzi

Pharmacological action: unknown

Components

Name UniProt ID Details
Trypanothione reductase P28593 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

3. Aspartate aminotransferase

Kind: protein

Organism: Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)

Pharmacological action: unknown

Components

Name UniProt ID Details
Aspartate aminotransferase Q56232 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

4. Aromatic-amino-acid aminotransferase

Kind: protein

Organism: Paracoccus denitrificans

Pharmacological action: unknown

Components

Name UniProt ID Details
Aromatic-amino-acid aminotransferase P95468 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

5. Aspartate aminotransferase, cytoplasmic

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Aspartate aminotransferase, cytoplasmic P17174 Details

References:

  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:24